New Trials Comparing Protease Inhibitors and Nonnucleoside Analogs will Assess Reductions in Cardiovascular Risk Besides Antiviral Efficacy in First-line Therapies
New Trials Comparing Protease Inhibitors and Nonnucleoside Analogs will Assess Reductions in Cardiovascular Risk Besides Antiviral Efficacy in First-line Therapies
Francisco Blanco
NULL
*Correspondence: Francisco Blanco, Email not available
Abstract
Boehringer Ingelheim recently announced theinitiation of a new clinical trial, called NewArT, thatwill compare the efficacy and safety of the NNRTInevirapine (Viramune®) versus the ritonavir-boostedprotease inhibitor atazanavir (Reyataz®, Bristol-Myers Squibb). The study will enroll 150 HIV treatment-naive patients from 18 planned sites acrossthe USA. Both agents will be combined with thefixed-dose combination of tenofovir and emtricitabine(Truvada®, Gilead Sciences).
